Depo-Provera brain tumor claims are paid through a global settlement that Pfizer and plaintiffs' lawyers reached in principle on June 15, 2026, covering eligible cases in the federal MDL and parallel New York state court. Judge M.
Casey Rodgers, who oversees the consolidated litigation in the Northern District of Florida, has not yet released the settlement's dollar amounts and instead scheduled a town hall to walk claimants through eligibility (Mealey's/LexisNexis). The litigation covers women who allege the injectable contraceptive Depo-Provera caused meningioma, a usually noncancerous tumor that grows from the membrane covering the brain and spinal cord. Thousands of cases are pending, most are expected to qualify, and a formal claims process is still taking shape.
Official resources:
- Read the official notice from Helbocklaw — Use this primary source to verify the official announcement.
- Read the official notice from Lawfold — Use this primary source to verify the official announcement.
Table of Contents
- What Is the Depo-Provera Litigation, and Who Is Being Sued?
- Has a Settlement Been Reached, and Who Qualifies?
- What Are the Expected Payout Amounts?
- Why Are These Brain Tumors Linked to Depo-Provera?
- What Should Someone With a Potential Claim Do Now?
- Frequently Asked Questions
What Is the Depo-Provera Litigation, and Who Is Being Sued?
The federal cases are consolidated as MDL No. 3140, assigned to Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida.
The defendants are Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. (mctlaw.com). As of a July 27, 2026 case management order, 6,289 Depo-Provera actions were pending across the MDL and coordinated New York and Delaware state court proceedings (vanlawfirm.com). Each case alleges that long-term use of the injectable birth control drug raised the plaintiff's risk of developing a meningioma, often requiring surgery or ongoing monitoring.
Has a Settlement Been Reached, and Who Qualifies?
Leadership Counsel told Judge Rodgers on June 15, 2026, that Pfizer and plaintiffs' attorneys reached a global settlement in principle, covering plaintiffs in the MDL and the parallel New York state court cases who meet agreed eligibility criteria (Mealey's/LexisNexis). The parties followed that announcement with a formal Master Settlement Agreement, signed around July 21-22, 2026. About 80% of pending federal MDL plaintiffs are expected to qualify as eligible claimants under the agreement's terms (vanlawfirm.com).
The remaining roughly 20% of filed cases are reported as ineligible, potentially excluding more than 1,000 women. Many of those exclusions stem from Pfizer's argument that the claims were filed outside the applicable statute of limitations, the legal deadline for bringing a lawsuit (vanlawfirm.com). Eligible MDL plaintiffs face a settlement-program registration deadline of November 30, 2026, though the exact claims-filing process was still unpublished as of the sources reviewed (vanlawfirm.com).
What Are the Expected Payout Amounts?
Judge Rodgers has not publicly released the settlement's financial terms. Instead, she scheduled a town hall meeting to explain eligibility requirements and other claim details directly to claimants (Mealey's/LexisNexis). No court-approved payout schedule or tier amounts exist yet.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
In the absence of official figures, law firm marketing pages have published their own unofficial estimates, and these numbers conflict sharply with each other. Helbock Law projects $500,000 to $1.5 million or more for cases involving craniotomy or permanent damage, while Lawfold estimates $50,000 to $150,000 for monitored meningiomas that did not require surgery. These figures come from individual firms, not the court or the settlement administrator, and should be treated as speculative rather than confirmed values until Judge Rodgers releases official terms.
Why Are These Brain Tumors Linked to Depo-Provera?
The connection between Depo-Provera and meningioma risk is grounded in both regulatory action and published research. The FDA approved a label change for Depo-Provera CI (150 mg, injected into muscle) and Depo-SubQ Provera 104 on December 12, 2025, adding a meningioma warning along with patient-counseling language and an updated Medication Guide. Pfizer had initially requested the change, the FDA denied it, and Pfizer resubmitted the request in June 2025 before it was approved (pedsendo.org).
The underlying science comes from a French case-control study published in BMJ in 2024. Researchers found that using medroxyprogesterone acetate, the hormone in Depo-Provera, for more than one year was linked to a 5.6-fold increase in the risk of intracranial meningioma severe enough to require surgery. The absolute risk remained low either way, about 0.05% among users compared with 0.01% in non-users, and the study's design could not prove that the drug directly caused the tumors (HealthDay/BMJ).
What Should Someone With a Potential Claim Do Now?
Anyone who used Depo-Provera long-term and was later diagnosed with a meningioma, especially one requiring surgery, has grounds to check whether they fall within the settlement's eligibility window. A few practical steps matter most right now: A case that was filed later than others, or one still being evaluated by an attorney, may still be added to the litigation before the registration deadline closes.
- Confirm the timeline of Depo-Provera use and meningioma diagnosis, since statute-of-limitations issues are already excluding roughly one in five filed cases.
- Watch for communication about the registration deadline of November 30, 2026, which applies to eligible MDL plaintiffs.
- Treat any payout number seen in advertising as a marketing estimate, not a confirmed amount, until Judge Rodgers releases official settlement terms.
- Attend or follow updates from the town hall meeting Judge Rodgers scheduled to explain eligibility requirements directly to claimants.
Frequently Asked Questions
Has Pfizer admitted that Depo-Provera causes brain tumors?
No. The settlement resolves claims without an admission; the FDA's December 2025 label update added a meningioma warning but did not state the drug causes the tumors.
What happens to the roughly 20% of cases deemed ineligible?
Reporting attributes most exclusions to Pfizer's statute-of-limitations argument, meaning those claims were filed after the applicable legal deadline, according to vanlawfirm.com's July 2026 update.
When will official payout amounts be released?
As of the August 2026 Mealey's report, Judge Rodgers had not released financial terms publicly and instead scheduled a town hall to cover eligibility details with claimants.
You Might Also Like
- Vaginal Mesh Lawsuit Settlements: Are Claims Still Open in October 2026?
- Monsanto Roundup Lawsuit Settlement Payouts Explained
- Depo-Provera Lawsuit: What the October Settlement Update Means for Claims